A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement. Doi Y, Yokota T, Shibayama H, Matsumoto K, et al. Leuk Lymphoma 2022;63:1013-1015.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Doi Y, Yokota T, Shibayama H, Matsumoto K, et al. A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement. Leuk Lymphoma 2022;63:1013-1015.
PMID: 34852707